First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
Ansell, S. M. Connors, J. M. Radford, John A Kim, W. S. Gallamini, A. Ramchandren, R. Friedberg, J. W. Advani, R. H. Hutchings, M. Evens, A. M.
Ansell, S. M.
Connors, J. M.
Radford, John A
Kim, W. S.
Gallamini, A.
Ramchandren, R.
Friedberg, J. W.
Advani, R. H.
Hutchings, M.
Evens, A. M.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ansell SM, Connors JM, Radford JA, Kim WS, Gallamini A, Ramchandren R, et al. First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301966.